MedTrace Logo

Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+

NCT01220076 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2021-03-12

No results posted yet for this study

Summary

The biological response to treatment with tamoxifen in the preoperative situation is studying in this protocol. This study will enrolls patients with non-metastatic breast cancer HR +.

The relationship between the CYP2D6 polymorphism, pharmacokinetics and biological efficacy of TAM will be studied.

Conditions

  • Non Metastatic Breast Cancer

Interventions

DRUG

tamoxifen

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01220076 on ClinicalTrials.gov